Louisville, KYNCT04879043Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in Louisville, KY

Access cutting-edge multiple myeloma treatment through this phase 1/2 clinical trial at a research site in Louisville. Study-provided care at no cost to qualified participants.

Sponsored by Heidelberg Pharma AG

Quick Self-Assessment

See if you qualify for this Louisville location

Preparing your pre-screening questions…

Expert Care in Louisville

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This Louisville Location

Check if you qualify for this multiple myeloma clinical trial in Louisville, KY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Louisville

    Convenient for KY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Louisville site if eligible
  4. 4Begin participation

About This Multiple Myeloma Study in Louisville

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

Sponsor: Heidelberg Pharma AG

Who Can Participate

Inclusion Criteria

Male or female aged ≥18 years.
Life expectancy \>12 weeks.
Eastern Cooperative Oncology Group Performance Status (PS) of 0 to 2.
A confirmed diagnosis of active MM according to the diagnostic criteria established by the International Myeloma Working Group (IMWG).
Must have undergone SCT or is considered transplant ineligible.
Must have undergone prior treatments with antimyeloma therapy which must have included an immunomodulatory drug, proteasome inhibitor, and anti-CD38 treatment, alone or in combination. In addition, the patient should either refractory or intolerant to any established standard of care therapy providing a meaningful clinical benefit for the patient assessed by the Investigator.
Measurable disease as per IMWG criteria.
Adequate organ system function as defined in protocol.

Exclusion Criteria

For patient entering the Phase 2a part only: Prior treatment with any approved or experimental BCMA-targeting modalities are not allowed.
Known central nervous system involvement.
Plasma cell leukemia.
History of congestive heart failure.
Autologous or allogenic SCT within 12 weeks before the first infusion or is planning for autologous SCT.
Symptomatic graft versus host disease post allogenic hemopoietic cell transplant within 12 months prior to the first study treatment infusion.
Radiotherapy within 21 days prior to the first study treatment infusion.
History of any other malignancy known to be active.
Known human immunodeficiency virus infection.
Patients with active infection requiring systemic anti-infective.
Patients with positive test results for hepatitis B surface antigen or Hepatitis B core antigen.
Patients with positive test results for hepatitis C virus (HCV) infection.
Current active liver or biliary disease.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Louisville?

Yes, this clinical trial (NCT04879043) has an active research site in Louisville, KY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Louisville, KY

If you're searching for multiple myeloma treatment options in Louisville, KY, this clinical trial (NCT04879043) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Louisville research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Louisville, KY

See all multiple myeloma clinical trials recruiting in Louisville — not just this study.

Browse Multiple Myeloma Trials in Louisville →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in Louisville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Louisville, KY